06/05/2026
Major News in Pancreatic Cancer Research!
For decades, researchers have been trying to target KRAS, the genetic mutation that drives more than 90% of pancreatic cancers. This week, the pancreatic cancer community received some of the most encouraging news we've seen in years.
A new targeted therapy called daraxonrasib demonstrated unprecedented results in a large Phase III clinical trial for patients with metastatic pancreatic cancer. Patients receiving the KRAS-targeted treatment experienced a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy; nearly doubling survival while also experiencing fewer severe side effects. Researchers reported a 60% reduction in the risk of death.
These results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) and are being described by experts as a potential turning point in pancreatic cancer treatment.
While this is not yet a cure, it represents something patients, survivors, caregivers, and researchers have been waiting for: real progress against KRAS, one of the most challenging targets in cancer research.
At the Seena Magowitz Foundation, we remain committed to supporting research, education, and patient programs that help bring hope and better outcomes to everyone affected by pancreatic cancer.
đź’ś Progress is happening.
đź’ś Hope is growing.
đź’ś We will continue fighting together.
